Subscribe


Pharmacy DailyAbout Pharmacy Daily

Pharmacy Daily is Australia’s favourite online publication dedicated to the pharmacy industry. The publication launched in March 2007 and is distributed every day by email to pharmacists across the country. Pharmacy Daily is aimed at people working in the pharmacy industry – pharmacists, dispensary assistants and shop staff as well as people working in manufacturing and hospital pharmacy. Currently more than 12,500 people read Pharmacy Daily, with numbers growing every day.

Pharmacy Daily is renowned for breaking the big pharmacy industry stories and has close links with the Pharmacy Guild, Pharmaceutical Society of Australia and other government and industry bodies as well as wholesalers and other suppliers, making the free publication the best way to keep fully informed about the industry.

Editorial Opportunities

Pharmacy Daily aims to bring the most up-to-date and relevant information to the industry each day. Accordingly we welcome any relevant newsworthy editorial – new products, news releases, appointments and any special offers. We also publish photographs of industry events and anything else of interest so keep those cameras handy!

If you need to reach the Australian pharmacy industry with timely, up-to-date information Pharmacy Daily is an ideal medium. All editorial contributions can be emailed to info@pharmacydaily.com.au or faxed to 1300 799 221 or +61 2 8007 6769.

Advertising

Pharmacy Daily is a highly cost-effective advertising medium for the pharmacy industry. Rates are extremely reasonable and because the newsletter is well-read it provides a targeted way to get your product out there.

Click here for more information about advertising in Pharmacy Daily.

How do I get Pharmacy Daily

Eligible industry staff can click here to register their details to receive Pharmacy Daily at no charge.

More Information

Anyone wanting more information on Pharmacy Daily can contact us on info@pharmacydaily.com.au, by phone on 1300 799 220 (within Australia) or +61 2 8007 6760 (overseas). Our fax number is 1300 799 221 (within Australia) or +61 2 8007 6769.



Latest Pharmacy Daily headlines

Thu 22 Feb 18

PD breaking news – Blackmores H1 profit up 20%


Pharmacy Daily

Blackmores H1 profit up 20%Blackmores has reported overall group revenue was boosted 9% to $287m for the six months to 31 Dec primarily from “consistent sales growth with improved profitability” and resulting in net profit after tax for shareholders at $34m, up 20% on the previous corresponding period.Revenue in Australia and New Zealand was $121m, slightly down from the previous year as the broader consumer market remained subdued and China-influenced sales continued to move to Blackmores’ direct China channels, directors said.


Thu 22 Feb 18

‘War’ not ‘jaw’ over code


Pharmacy Daily

IN AN unflinchingly direct letter to the Department of Health First Assistant Secretary Ross Hawkins, Friends of Science advocate and public health protagonist Associate Professor Ken Harvey of Monash University has called for "respect and constructive outcomes".


Thu 22 Feb 18

Community pharmacy tick


Pharmacy Daily

THE Australian "tried and trusted community pharmacy model" received a shot in the arm with the passage through Federal Parliament last week of amendments that removed the sunset clause on the Pharmacy Location Rules (PD 14 Feb), Pharmacy Guild of Australia executive director David Quilty writes.


Wed 21 Feb 18

CW nets major partnership


AUSTRALIAN pharmacy discount retail group Chemist Warehouse has again linked with Beach Netball ("It's netball, but not as you know it") as a major partner and is gearing up to support the upcoming 2018 series across the country.


Wed 21 Feb 18

EBOS H1 earnings up 15.6%


Pharmacy Daily

ASX-LISTED marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products EBOS, has announced a record interim unaudited net profit of $76.7m for the six months to 31 Dec 2017, with EBITDA up 15.6% and net profit after tax up 11.5%.


Wed 21 Feb 18

Gabapentinoid abuse up


THE US Food and Drug Administration (FDA) is actively looking into the potential misuse and abuse of gabapentinoids, a class of drugs that includes Pfizer's Neurontin (gabapentin) and Lyrica (pregabalin), which have been approved to treat a number of conditions such as postherpetic neuralgia, fibromyalgia and neuropathic pain.


View All news articles Subscribe to the Newsletter